Celanese Announces Acetyl Intermediate Price Increases
Get Alerts CE Hot Sheet
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 1.8%
EPS Growth %: -5.0%
Join SI Premium – FREE
DALLAS & SHANGHAI--(BUSINESS WIRE)-- Celanese Corporation (NYSE: CE), a global chemical and specialty materials company, will increase list and off-list selling prices for the following acetyl intermediate products. The price increases below will be effective immediately, or as contracts otherwise allow, and are incremental to any previously announced increases.
|
AOC |
GC |
Product |
(USD/MT) |
(RMB/MT) |
Acetic Acid |
$100 |
CNY 600 |
Vinyl Acetate Monomer |
$200 |
CNY 1,500 |
Ethyl Acetate / Butyl Acetate |
$50 |
-- |
Acetic Anhydride |
$100 |
CNY 600 |
VAE Emulsions |
$100 |
CNY 700 |
Redispersable Powders |
$150 |
CNY 1,000 |
About Celanese
Celanese Corporation is a global chemical leader in the production of differentiated chemistry solutions and specialty materials used in most major industries and consumer applications. Our businesses use the full breadth of Celanese's global chemistry, technology and commercial expertise to create value for our customers, employees, shareholders and the corporation. As we partner with our customers to solve their most critical business needs, we strive to make a positive impact on our communities and the world through The Celanese Foundation. Based in Dallas, Celanese employs approximately 8,500 employees worldwide and had 2021 net sales of $8.5 billion. For more information about Celanese Corporation and its product offerings, visit www.celanese.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220525006028/en/
Celanese Contacts:
Investor Relations
Brandon Ayache
+1 972 443 8509
[email protected]
Media Relations – Global
W. Travis Jacobsen
+1 972 443 3750
[email protected]
Media Relations Europe (Germany)
Petra Czugler
+49 69 45009 1206
[email protected]
Source: Celanese Corporation
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Newmont Reports First Quarter 2024 Results
- Comcast Reports 1st Quarter 2024 Results
- HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
Raising PricesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!